A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.
about
First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studiesBisphosphonates in multiple myelomaEarly versus deferred treatment for early stage multiple myelomaImmunological factors and risk of infection in plateau phase myelomaA review for solitary plasmacytoma of bone and extramedullary plasmacytomaLaminin-1-induced migration of multiple myeloma cells involves the high-affinity 67 kD laminin receptorCriteria for diagnosis, staging, risk stratification and response assessment of multiple myelomaPrognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging systemMultiple myelomaThe use of intravenous immune globulin in multiple myelomaProblems monitoring response in multiple myelomaThe Prevalence and Management of Multiple Myeloma-Induced Kidney Disease in ChinaDoes my patient with a serum monoclonal spike have multiple myeloma?¹⁸F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic reviewImaging of multiple myeloma: Current conceptsSmoldering multiple myeloma requiring treatment: time for a new definition?Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementDiagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvementGlomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myelomaCombination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitorsAnalysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14)Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11)Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature.Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients.Understanding neural networks using regression trees: an application to multiple myeloma survival data.Role of dynamic contrast-enhanced sonography for characterization and monitoring of extramedullary myeloma: comparison with serologic data.Penalized partial likelihood regression for right-censored data with bootstrap selection of the penalty parameter.Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature.Multiple myeloma in elderly patients: presenting features and outcome.Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomizeTesting standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma.Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma.Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma--the DD Protocol.Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma.Bortezomib: the evidence of its clinical impact in multiple myeloma.Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma.Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.
P2860
Q24197999-D478EBDB-FFE2-4A83-8FE5-42CA31EDA653Q24236776-E24D5609-94E2-4465-8199-F71C08E93A63Q24250249-0B934945-1567-426E-8295-11CC570C3ACFQ24563519-34519EA8-9D1B-41D9-BFA7-2BE1541A4811Q24619913-1099AE13-ABF5-45CB-AA52-EDB1D533502BQ24642958-C31C4D29-7EB1-4982-8646-62340523DD41Q24647620-7C522D55-7358-4A57-8DED-6A693AD3744DQ24653434-382B9287-C997-4D14-B4F1-A733789C2DA7Q24655964-6E8403F4-2E1C-453D-B225-35AB369534B2Q24675078-786AA350-1534-4559-9ADA-E56F5A79CC28Q24676888-EEFEBA65-9C13-4BA5-8AF3-28605C2F4B55Q26740446-F7681592-9DFF-41E9-ACDD-84A15392CEC9Q26821981-F4963E7F-6F9B-4199-BF1D-D35FCEB5BDD9Q26823362-8795F6FB-F0E6-4B5F-A9B9-39B54488949DQ26864616-2787CDEE-CCB9-424E-A788-DF4A20EB23CCQ26996579-DD9EBCEE-E22A-4067-B55F-5F5C85AA21FCQ26998884-22DF036D-B089-48A3-A54F-1847BF325E96Q27011865-7C09CB0B-2242-4095-A13B-DC55B32FA05CQ28345363-E0A0AEB8-E851-4CBD-B184-305621133ABDQ28537997-5DE44658-72C5-4B98-A973-37682DCFA7E7Q28678621-1D00CAD0-5E30-464B-8146-D4897F9B706CQ30397259-7107C00A-3FAB-4457-9A6F-71B73F5E4D9CQ30409713-6366A6F5-8CE4-4521-AB3F-71DBCECCE4BCQ30585098-C5FF5F18-6A67-47FD-BE6B-7CFE15D8E548Q30655745-2689830C-45E4-4CCF-BC40-18AE77ECF4E1Q30661154-96BE0DDC-902C-475A-8DA4-618E124D24FBQ30669943-D71379F8-4B86-4359-9E10-2C5811AF8ED7Q30757226-0F6D06D7-1BDB-4B59-BD61-A3213323A7DFQ31146661-4D7FA219-9E64-46DD-ACB6-A446DC2EF486Q31899278-10D55E22-F167-4C49-80E3-5A65F478E1F2Q31899323-670DA4A7-AE91-419E-8B41-AD7E106F1F91Q33284138-15140D3B-1B45-470D-9BF9-BB91D01E3DBEQ33342798-D4E580D9-6B62-4AEA-8EF9-0F9F8C6F31BBQ33343492-33E5A0B5-140F-4140-863D-1973A3157784Q33370094-6F2304DD-844D-4E74-BDE2-70644FB278D0Q33397490-6C075DA3-3574-457B-BE49-B57D8FB693F7Q33400724-AA702CB2-544F-4B35-8B47-6C0579F56C8FQ33400871-91DEF718-A986-4713-835B-547FC1148FF1Q33402671-16415468-22B6-49CA-B4B4-2985A26A9591Q33404570-A00EAA32-450E-40F8-933A-235DF2E54C23
P2860
A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.
description
1975 nî lūn-bûn
@nan
1975 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1975 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1975年の論文
@ja
1975年論文
@yue
1975年論文
@zh-hant
1975年論文
@zh-hk
1975年論文
@zh-mo
1975年論文
@zh-tw
1975年论文
@wuu
name
A clinical staging system for ...... se to treatment, and survival.
@ast
A clinical staging system for ...... se to treatment, and survival.
@en
type
label
A clinical staging system for ...... se to treatment, and survival.
@ast
A clinical staging system for ...... se to treatment, and survival.
@en
prefLabel
A clinical staging system for ...... se to treatment, and survival.
@ast
A clinical staging system for ...... se to treatment, and survival.
@en
P1433
P1476
A clinical staging system for ...... se to treatment, and survival.
@en
P2093
P304
P356
10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U
P407
P577
1975-09-01T00:00:00Z